Literature DB >> 7811025

Dissociated resistance among fluoroquinolones.

K S Thomson1, C C Sanders.   

Abstract

A panel of 190 clinical isolates of staphylococci, enterococci, Streptococcus pneumoniae, members of the family Enterobacteriaceae, and nonfermentative gram-negative bacilli were examined by agar dilution tests for susceptibility to five quinolones and six nonquinolone agents. Members of the family Enterobacteriaceae and staphylococci were divided into subgroups according to their ciprofloxacin susceptibilities and were analyzed for cross-resistance to OPC-17116, ofloxacin, and temafloxacin. Although the MICs of all quinolones increased with increasing ciprofloxacin resistance, the MICs of OPC-17116, ofloxacin, and temafloxacin tended to increase less than those of ciprofloxacin, indicating that these agents were less affected by the mechanisms of quinolone resistance. An exception to this was the activity of OPC-17116 against highly ciprofloxacin-resistant staphylococci (MIC, > or = 8 micrograms/ml). Some of these staphylococci were equally resistant to OPC-17116, while others were fourfold more susceptible to ciprofloxacin than to OPC-17116. This indicated that in some strains OPC-17116 was more affected than ciprofloxacin by certain mechanisms responsible for high-level resistance. This was paralleled in single-step mutational studies in which 7 of 19 staphylococcal mutants exhibited large decreases in susceptibility to OPC-17116 (128- to 256-fold) but only modest decreases in susceptibility (4- to 16-fold) to the other quinolones. Such mutants were selected only from strains moderately resistant to ciprofloxacin (MIC, > or = 1 microgram/ml). This heterogeneity in the resistance of staphylococci to fluoroquinolones has not been seen previously and suggests that certain mechanisms of resistance in staphylococci affect OPC-17116 to a much greater extent than other quinolones.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811025      PMCID: PMC284690          DOI: 10.1128/AAC.38.9.2095

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.

Authors:  K S Thomson; C C Sanders; M E Hayden
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

2.  In vitro activity of OPC-17116.

Authors:  H C Neu; W Fang; J W Gu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors:  T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.

Authors:  H S Sader; M E Erwin; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  5 in total
  7 in total

1.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

2.  In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.

Authors:  M C Struwig; P L Botha; L J Chalkley
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 3.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

4.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 5.  Grepafloxacin.

Authors:  A J Wagstaff; J A Balfour
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

6.  Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones.

Authors:  T Takenouchi; C Ishii; M Sugawara; Y Tokue; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

7.  Evolution of antibiotic cross-resistance and collateral sensitivity in Staphylococcus epidermidis using the mutant prevention concentration and the mutant selection window.

Authors:  Natalie Ann Lozano-Huntelman; Nina Singh; Alondra Valencia; Portia Mira; Maral Sakayan; Ian Boucher; Sharon Tang; Kelley Brennan; Crystal Gianvecchio; Sorel Fitz-Gibbon; Pamela Yeh
Journal:  Evol Appl       Date:  2020-02-25       Impact factor: 5.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.